Undifferentiated Carcinoma
Conditions
Keywords
tumoroid, organoid
Brief summary
The study is based on the constitution of a collection of tumor and blood samples for the development of tumoroid for functional tests to predict clinical response to treatment.
Interventions
OTHERorganoid etablishment
Prior to initiation of 1st-line therapy: * Collection of an additional study-specific tumor sample for tumoroid analysis (1 fresh tumor sample) * A blood test blood a for tumoroid realization and : * Analysis of ex vivo tumoroid response to treatment and correlation with patient response in vivo * Analysis of correlation between in vivo and ex vivo tumor characteristics * Analysis of first- and second-line survival rates and overall survival
Sponsors
Centre Francois Baclesse
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with undifferentiated primary carcinoma (UPC) with histological and immunohistochemical evidence, validated in a local and/or national UPC multidisciplinary consultation * Patient with indication for systemic 1st-line treatment at the time of inclusion. Treatment may already have begun at the time of inclusion, but within the limit of 2 treatment cycles administered. * Patient with life expectancy greater than 3 months * Patient of legal age * Patient affiliated to a social security scheme * Signature of informed consent prior to any specific study procedure
Exclusion criteria
* Persons deprived of their liberty or under guardianship (including curatorship) * Pregnant or breast-feeding patient
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of establishment of exploitable tumor organoids | through study completion, an average of 3 years | Rate of establishment usable tumor organoids for predictive tests of response to treatment. |
Countries
France
Contacts
Primary Contactzoé NEVIERE, Medical Doctor
Outcome results
None listed